Gilbert Egekeze, MD
Internal Medicine · Crystal Lake, ILNPI 1548361959
Payments from drug & device makers
Across 382 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$951
- AbbVie$799
- GSK$402
- Johnson & Johnson$347
- AstraZeneca$257
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,17099%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,266 |
| Pfizer | 62 | $951 |
| AbbVie(2 entities) | 45 | $799 |
| GSK | 25 | $402 |
| Johnson & Johnson | 27 | $347 |
| AstraZeneca | 13 | $257 |
| Amarin Pharma, Inc. | 14 | $206 |
| Abbott | 9 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $168 |
| Boehringer Ingelheim | 9 | $156 |
| Otsuka America Pharmaceutical, Inc. | 7 | $144 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Astellas Pharma US Inc | 6 | $117 |
| Lilly USA, LLC | 6 | $110 |
| Novartis | 7 | $107 |
| Sunovion Pharmaceuticals Inc. | 7 | $105 |
| Dexcom, Inc. | 5 | $96 |
| Exact Sciences | 4 | $88 |
| Eisai Inc. | 4 | $75 |
| Hologic Sales And Service, LLC | 4 | $69 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $49 |
| Lundbeck LLC | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Edwards Lifesciences | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Urovant Sciences Inc | 1 | $20 |
| Bayer | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$6,249 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $114,454 |
| OzempicSemaglutide | 61 | $70,778 |
| XareltoRivaroxaban | 78 | $52,240 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $37,433 |
| JardianceEmpagliflozin | 46 | $28,021 |
| JanuviaSitagliptin Phosphate | 33 | $22,754 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $21,905 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $15,331 |
| TrulicityDulaglutide | 21 | $13,101 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $13,037 |
| LinzessLinaclotide | 20 | $10,782 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $10,118 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $9,331 |
| Bumetanide | 187 | $8,496 |
| MyrbetriqMirabegron | 11 | $8,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $951 | $114,454136 claims |
| Novo NordiskOzempic | $1,266 | $70,77861 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $402 | $66,68082 claims |
| Johnson & JohnsonXarelto | $347 | $52,24078 claims |
| Boehringer IngelheimJardiance | $156 | $28,02146 claims |
| AbbVieLinzess, Combigan | $799 | $14,07035 claims |
| Lilly USA, LLCTrulicity | $110 | $13,10121 claims |
| Astellas Pharma US IncMyrbetriq | $117 | $8,40911 claims |
| AstraZenecaBrilinta | $257 | $7,46416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Crystal Lake
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.